CADL - Candel Therapeutics Inc
IEX Last Trade
6.75
0.370 5.481%
Share volume: 342,735
Last Updated: Fri 30 Aug 2024 09:59:28 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.38
0.37
5.80%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-12 | 2022-08-05 | 2022-11-10 | 2023-03-30 | 2023-05-11 | 2023-08-10 | 2023-11-09 | |
| Assets | ||||||||
| Total Assets | 101.562 M | 93.301 M | 85.007 M | 77.691 M | 67.238 M | 58.708 M | 50.061 M | |
| Current Assets | 95.646 M | 87.326 M | 79.070 M | 71.945 M | 61.875 M | 53.362 M | 45.101 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.325 M | 544.000 K | 1.887 M | 1.887 M | 2.617 M | 1.468 M | 2.118 M | |
| Short Term Investments | 1.325 M | 544.000 K | 1.887 M | 1.887 M | 2.617 M | 1.468 M | 2.118 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 94.321 M | 86.782 M | 77.183 M | 70.058 M | 59.258 M | 51.894 M | 42.983 M | |
| Total Non-current Assets | 5.916 M | 5.975 M | 5.937 M | 5.746 M | 5.363 M | 5.346 M | 4.960 M | |
| Property Plant Equipment | 4.264 M | 4.545 M | 4.561 M | 4.424 M | 4.098 M | 3.981 M | 3.676 M | |
| Other Assets | 1.215 M | 1.164 M | 1.110 M | 1.056 M | 999.000 K | 1.099 M | 1.018 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 101.562 M | 93.301 M | 85.007 M | 77.691 M | 67.238 M | 58.708 M | 50.061 M | |
| Total liabilities | 37.800 M | 33.229 M | 32.880 M | 29.977 M | 27.586 M | 27.937 M | 27.039 M | |
| Total current liabilities | 5.472 M | 5.878 M | 5.898 M | 5.615 M | 5.236 M | 8.163 M | 10.327 M | |
| Accounts Payable | 1.386 M | 1.584 M | 970.000 K | 380.000 K | 592.000 K | 480.000 K | 250.000 K | |
| Other liabilities | 9.965 M | 4.996 M | 4.626 M | 2.026 M | 1.290 M | 1.134 M | 541.000 K | |
| Current long term debt | 429.000 K | 440.000 K | 452.000 K | 464.000 K | 1.729 M | 4.140 M | 6.600 M | |
| Long term debt | 22.363 M | 22.355 M | 22.356 M | 22.336 M | 21.060 M | 18.640 M | 16.171 M | |
| Other liabilities | 9.965 M | 4.996 M | 4.626 M | 2.026 M | 1.290 M | 1.134 M | 541.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 63.762 M | 60.072 M | 52.127 M | 47.714 M | 39.652 M | 30.771 M | 23.022 M | |
| Common stock | 28.691 M | 28.810 M | 28.892 M | 28.901 M | 28.920 M | 28.920 M | 28.920 M | |
| Retained earnings | -81.169 M | -85.318 M | -94.006 M | -99.089 M | -107.884 M | -117.498 M | -125.933 M |